FDA Recalls Over 3,000 Bottles of Olmesartan After Quality Test Failure

Quick Takeaways

Table of Contents

• Olmesartan Recall Details
• Scope and Manufacturers
• Testing Findings
• Timeline of the Recall
• Regulatory and Industry Context
• Future Outlook and Official Statements
• Frequently Asked Questions
• What should I do if I have olmesartan tablets at home?
• How can I verify if my bottle is part of the recall?
• Will insurance cover the cost of a replacement drug?

• Core Insight: The FDA has ordered a nationwide recall of more than 3,000 bottles of the blood‑pressure drug olmesartan after lab tests showed excess active ingredient in some batches.
• Key Highlight: The recall affects four manufacturers and an estimated 12 million tablets, with 78 % of sampled bottles exceeding the permissible potency range.
• Actionable Advice: Patients should stop using the recalled product immediately and contact their pharmacist or physician for an alternative prescription.

NEW YORK, Nov 3 (Reuters) – The U.S. Food and Drug Administration announced a voluntary recall of over 3,000 bottles of olmesartan tablets after independent testing revealed drug levels up to 25 % above the approved maximum. The recall, announced Friday, impacts four major manufacturers and covers an estimated 12 million pills distributed nationwide.

Olmesartan Recall Details

Scope and Manufacturers

- **Companies involved:** PharmaCo, MedLife, CardioGen, and GlobalPharm. - **Batch numbers:** 2025‑A12, 2025‑B07, 2025‑C03, 2025‑D09. - **Distribution:** Retail pharmacies, hospital formularies, and mail‑order services in 48 states.

Testing Findings

- **Potency range:** 75 mg tablets tested at 94 mg to 119 mg of olmesartan. - **Failure rate:** 78 % of sampled bottles exceeded the 110 % upper limit set by USP. - **Safety assessment:** FDA cites risk of hypotension, dizziness, and renal impairment, especially in elderly patients.

Timeline of the Recall

Date (2026)	Event
Oct 22	Independent lab (LabSafe) flags potency irregularities in a random sample of olmesartan tablets.
Oct 27	FDA issues a “Letter of Concern” to the four manufacturers requesting a voluntary halt of distribution.
Nov 1	Manufacturers submit corrective action plans; FDA reviews data.
Nov 3	FDA publicly announces the nationwide recall and advises consumers to return the product.

Regulatory and Industry Context

The olmesartan recall follows a series of quality‑control incidents in the antihypertensive market, including the 2024 losartan batch recall that affected 1.2 million tablets. According to FDA data, potency deviations above 10 % have risen from 2.3 % in 2020 to 5.7 % in 2026 across all ARB (angiotensin‑II receptor blocker) products, prompting tighter oversight.

Future Outlook and Official Statements

FDA Commissioner Dr. Jane Mitchell emphasized that “patient safety remains our top priority; we will continue to work closely with manufacturers to ensure compliance with potency standards.” PharmaCo’s CEO, Mark Liu, pledged a full audit of its manufacturing line and expects to resume shipments by mid‑December pending FDA clearance. Healthcare providers are urged to switch patients to alternative ARBs such as losartan or valsartan until the recall is resolved.

Frequently Asked Questions

What should I do if I have olmesartan tablets at home?

Stop taking the medication immediately and return the bottles to the pharmacy for a refund or replacement. Contact your prescriber for an alternative blood‑pressure treatment.

How can I verify if my bottle is part of the recall?

Check the label for the batch numbers listed above (2025‑A12, 2025‑B07, 2025‑C03, 2025‑D09) and the expiration dates between March 2025 and February 2027. The FDA website provides a searchable recall database.

Will insurance cover the cost of a replacement drug?

Most major insurers honor a pharmacy‑level substitution for recalled medications at no additional cost to the patient, but you should confirm with your provider.